Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

NCT07224360 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease

Interventions

BIOLOGICAL: Anumigilimab
DRUG: Placebo

Sponsor

CSL Behring